\-\ Texto\\:\\ \ \(0\)\
\-\ decreased\\ range\\ of\\ motion\\ of\\ right\\ hip\\ secondary\\ to\\ pain\\.\ \(0\)\
\-\ labs\\ normal\\.\ \(1\)\
\-\ hip\\ replacement\\ is\\ the\\ best\\ treatment\\,\\ however\\ this\\ patient\\ was\\ a\\ poor\\ surgical\\ candidate\\ and\\ was\\ treated\\ with\\ oral\\ pain\\ meds\\ and\\ facet\\ blocks\\.\ \(0\)\
\-\ x\\-ray\\:\\ serpntine\\ sclerotic\\ densities\\ in\\ the\\ both\\ femoral\\ heads\ \(0\)\
\-\ nuclear\\ scan\\:\\ focal\\ areas\\ of\\ photopenia\\ in\\ the\\ femoral\\ heads\\ with\\ surrounding\\ mild\\-to\\-moderate\\ increased\\ uptake\\ in\\ the\\ subcapital\\ areas\\ and\\ acetabuli\\.\\ \ \(0\)\
\-\ mri\\:\\ serpentine\\ areas\\ of\\ hypointensity\\ seen\\ in\\ the\\ bilateral\\ femoral\\ heads\\ on\\ t2\\ images\\.\\ \\ increased\\ t2\\ signal\\ seen\\ in\\ the\\ remaining\\ marrow\\ and\\ femoral\\ necks\\.\ \(0\)\
\-\ bilateral\\ avascular\\ necrosis\\ \\(avn\\)\\ of\\ the\\ femoral\\ heads\ \(0\)\
\-\ avn\\ \\(avascular\\ necrosis\\)\ \(0\)\
\-\ fracture\\ secondary\\ to\\ fall\ \(0\)\
\-\ osteoarthritis\ \(102\)\
\-\ inability\\ to\\ bear\\ weight\\ on\\ right\\ hip\\ with\\ constant\\,\\ severe\\,\\ non\\-radiating\\ pain\\ of\\ abrupt\\ onset\\.\\ \\ patient\\ fell\\ yesterday\\.\ \(0\)\
\-\ male\\ to\\ female\\ ratio\\ for\\ avn\\ is\\ 8\\ to\\ 1\\.\\ etiologies\\ are\\ numerous\\,\\ however\\,\\ in\\ non\\-taumatic\\ cases\\ the\\ etiology\\ is\\ poorly\\ understood\\.\\ \\ glucocorticoid\\ steroid\\ use\\ and\\ excessive\\ alcohol\\ intake\\ are\\ reported\\ to\\ account\\ for\\ more\\ than\\ 90\\ percent\\ of\\ cases\\.\ \(0\)\
\-\ one\\ possible\\ mechanism\\ of\\ steroid\\-induced\\ osteonecrosis\\ involves\\ alterations\\ in\\ circulating\\ lipids\\ with\\ resultant\\ microemboli\\ in\\ the\\ arteries\\ supplying\\ bone\\.\\ a\\ newer\\ theory\\ proposes\\ that\\ steroids\\ induce\\ changes\\ in\\ venous\\ endothelial\\ cells\\,\\ leading\\ to\\ stasis\\,\\ increased\\ intraosseous\\ pressure\\,\\ and\\ eventual\\ necrosis\\.\\ excessive\\ alcohol\\ use\\ and\\ the\\ development\\ of\\ osteonecrosis\\ have\\ been\\ linked\\ for\\ decades\\;\\ fat\\ emboli\\,\\ venous\\ stasis\\,\\ and\\ increased\\ cortisol\\ levels\\ have\\ all\\ been\\ implicated\\ as\\ etiologic\\ factors\\.\\ \\ \ \(0\)\
\-\ patients\\ with\\ sle\\ who\\ have\\ taken\\ glucocorticoids\\ are\\ at\\ greatest\\ risk\\,\\ although\\ occasional\\ cases\\ have\\ been\\ noted\\ in\\ the\\ absence\\ of\\ steroid\\ therapy\\.\\ \\ in\\ addition\\ to\\ their\\ role\\ in\\ patients\\ with\\ sle\\,\\ antiphospholipid\\ antibodies\\ may\\ be\\ associated\\ with\\ an\\ increased\\ risk\\ of\\ osteonecrosis\\ in\\ other\\ individuals\\.\\ fracture\\ or\\ dislocation\\ may\\ cause\\ damage\\ to\\ the\\ extraosseous\\ blood\\ vessels\\ supplying\\ the\\ affected\\ region\\.\\ \ \(0\)\
\-\ osteonecrosis\\ is\\ common\\ in\\ patients\\ with\\ homozygous\\ sickle\\ cell\\ disease\\.\\ approximately\\ 50\\ percent\\ of\\ affected\\ patients\\ develop\\ osteonecrosis\\ by\\ the\\ age\\ of\\ 35\\.\\ \\ gaucher\\ disease\\ results\\ in\\ the\\ accumulation\\ of\\ cerebroside\\-filled\\ cells\\ within\\ the\\ bone\\ marrow\\.\\ this\\ process\\ may\\ lead\\ to\\ compression\\ of\\ the\\ vasculature\\ and\\ subsequent\\ osteonecrosis\\.\\ \\ \\ osteonecrosis\\ can\\ occur\\ following\\ renal\\ transplantation\\,\\ but\\ usually\\ multifocal\\.\\ ther\\ is\\ increased\\ prevalence\\ with\\ thrombophillic\\ disorders\\ such\\ as\\ the\\ factor\\ v\\ leiden\\ mutation\\.\\ \\ hiv\\ may\\ confer\\ an\\ increased\\ risk\\ of\\ developing\\ osteonecrosis\\ of\\ the\\ femoral\\ head\\ as\\ well\\ as\\ individuals\\ undergoing\\ radiation\\ therapy\\.\\ \\ \ \(0\)\
\-\ there\\ are\\ two\\ types\\ of\\ osteonecrosis\\ limited\\ to\\ children\\:\\ idiopathic\\ osteonecrosis\\ of\\ the\\ femoral\\ head\\ \\(legg\\-calv\\?\\-perthes\\ disease\\)\\;\\ and\\ osteonecrosis\\ occurring\\ in\\ children\\,\\ usually\\ adolescents\\,\\ with\\ a\\ slipped\\ capital\\ femoral\\ epiphysis\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ osteonecrosis\\:\\ 0\\.12390122909474932\ \(0\)\
\-\ femoral\\:\\ 0\\.05569161484614655\ \(0\)\
\-\ heads\\:\\ 0\\.04435059755237784\ \(0\)\
\-\ avn\\:\\ 0\\.037715713778158834\ \(0\)\
\-\ increased\\:\\ 0\\.03133488966294987\ \(0\)\
\-\ supplying\\:\\ 0\\.02676903240473217\ \(0\)\
\-\ stasis\\:\\ 0\\.024715186236587045\ \(0\)\
\-\ excessive\\:\\ 0\\.02217529877618892\ \(0\)\
\-\ hip\\:\\ 0\\.02186641780799652\ \(0\)\
\-\ sle\\:\\ 0\\.021849877333028653\ \(0\)\
\-\ necrosis\\:\\ 0\\.021668741199858916\ \(0\)\
\-\ individuals\\:\\ 0\\.021357075064143055\ \(0\)\
\-\ avascular\\:\\ 0\\.020148370705752407\ \(0\)\
\-\ percent\\:\\ 0\\.019942763771335446\ \(0\)\
\-\ risk\\:\\ 0\\.019883554479822825\ \(0\)\
\-\ steroid\\:\\ 0\\.0193209992752134\ \(0\)\
\-\ patients\\:\\ 0\\.018942823120908146\ \(0\)\
\-\ serpntine\\:\\ 0\\.018876913113418627\ \(0\)\
\-\ non\\-taumatic\\:\\ 0\\.018876913113418627\ \(0\)\
\-\ cerebroside\\-filled\\:\\ 0\\.018876913113418627\ \(0\)\
\-\ thrombophillic\\:\\ 0\\.018876913113418627\ \(0\)\
\-\ areas\\:\\ 0\\.018471180971602143\ \(0\)\
\-\ alcohol\\:\\ 0\\.018435370096144106\ \(0\)\
\-\ cases\\:\\ 0\\.018287864222576868\ \(0\)\
\-\ subcapital\\:\\ 0\\.017392657908793477\ \(0\)\
\-\ steroid\\-induced\\:\\ 0\\.017392657908793477\ \(0\)\
\-\ lipids\\:\\ 0\\.017392657908793477\ \(0\)\
\-\ microemboli\\:\\ 0\\.017392657908793477\ \(0\)\
\-\ proposes\\:\\ 0\\.017392657908793477\ \(0\)\
\-\ antiphospholipid\\:\\ 0\\.017392657908793477\ \(0\)\
\-\ legg\\-calv\\:\\ 0\\.017392657908793477\ \(0\)\
\-\ \\-perthes\\:\\ 0\\.017392657908793477\ \(0\)\
\-\ mild\\-to\\-moderate\\:\\ 0\\.016524424272587556\ \(0\)\
\-\ marrow\\:\\ 0\\.01609966860221923\ \(0\)\
\-\ may\\:\\ 0\\.016054204444523545\ \(0\)\
\-\ extraosseous\\:\\ 0\\.015908402704168326\ \(0\)\
\-\ confer\\:\\ 0\\.015908402704168326\ \(0\)\
\-\ have\\:\\ 0\\.015849576688351966\ \(0\)\
\-\ affected\\:\\ 0\\.0158352231758019\ \(0\)\
\-\ children\\:\\ 0\\.015809655008836142\ \(0\)\
\-\ acetabuli\\:\\ 0\\.015430579253816698\ \(0\)\
\-\ necks\\:\\ 0\\.015430579253816698\ \(0\)\
\-\ etiologic\\:\\ 0\\.015430579253816698\ \(0\)\
\-\ homozygous\\:\\ 0\\.015430579253816698\ \(0\)\
\-\ 35\\.\\:\\ 0\\.015430579253816698\ \(0\)\
\-\ non\\-radiating\\:\\ 0\\.015040169067962406\ \(0\)\
\-\ glucocorticoid\\:\\ 0\\.015040169067962406\ \(0\)\
\-\ alterations\\:\\ 0\\.015040169067962406\ \(0\)\
\-\ induce\\:\\ 0\\.015040169067962406\ \(0\)\
\-\ leiden\\:\\ 0\\.015040169067962406\ \(0\)\
\-\ been\\:\\ 0\\.014934442544736559\ \(0\)\
\-\ photopenia\\:\\ 0\\.014710081959124594\ \(0\)\
\-\ yesterday\\:\\ 0\\.014710081959124594\ \(0\)\
\-\ circulating\\:\\ 0\\.014710081959124594\ \(0\)\
\-\ cells\\:\\ 0\\.014674289910706628\ \(0\)\
\-\ use\\:\\ 0\\.014464407344939199\ \(0\)\
\-\ in\\:\\ 0\\.014437592467332075\ \(0\)\
\-\ ther\\:\\ 0\\.014424147499543174\ \(0\)\
\-\ newer\\:\\ 0\\.014171935431756485\ \(0\)\
\-\ blocks\\:\\ 0\\.013946324049191548\ \(0\)\
\-\ implicated\\:\\ 0\\.013946324049191548\ \(0\)\
\-\ cortisol\\:\\ 0\\.013742233728411409\ \(0\)\
\-\ endothelial\\:\\ 0\\.013555913863337255\ \(0\)\
\-\ theory\\:\\ 0\\.013384516202366085\ \(0\)\
\-\ venous\\:\\ 0\\.013283878451636527\ \(0\)\
\-\ understood\\:\\ 0\\.013225826754499443\ \(0\)\
\-\ glucocorticoids\\:\\ 0\\.013225826754499443\ \(0\)\
\-\ antibodies\\:\\ 0\\.013225826754499443\ \(0\)\
\-\ gaucher\\:\\ 0\\.012939892294918024\ \(0\)\
\-\ adolescents\\:\\ 0\\.012939892294918024\ \(0\)\
\-\ eventual\\:\\ 0\\.012810075117580904\ \(0\)\
\-\ serpentine\\:\\ 0\\.012357593118293523\ \(0\)\
\-\ transplantation\\:\\ 0\\.012162792736696678\ \(0\)\
\-\ intraosseous\\:\\ 0\\.012071658658712103\ \(0\)\
\-\ linked\\:\\ 0\\.012071658658712103\ \(0\)\
\-\ capital\\:\\ 0\\.01198424539421477\ \(0\)\
\-\ decades\\:\\ 0\\.011741571549874291\ \(0\)\
\-\ mutation\\:\\ 0\\.011666429537430459\ \(0\)\
\-\ hypointensity\\:\\ 0\\.011593835208360477\ \(0\)\
\-\ slipped\\:\\ 0\\.011593835208360477\ \(0\)\
\-\ bear\\:\\ 0\\.011389744887580338\ \(0\)\
\-\ abrupt\\:\\ 0\\.011325819912955754\ \(0\)\
\-\ candidate\\:\\ 0\\.011263748099522665\ \(0\)\
\-\ meds\\:\\ 0\\.011263748099522665\ \(0\)\
\-\ intake\\:\\ 0\\.011263748099522665\ \(0\)\
\-\ prevalence\\:\\ 0\\.011263748099522665\ \(0\)\
\-\ constant\\:\\ 0\\.01114475484223185\ \(0\)\
\-\ usually\\:\\ 0\\.011113183100071774\ \(0\)\
\-\ as\\:\\ 0\\.011071327673611374\ \(0\)\
\-\ role\\:\\ 0\\.010822951409578022\ \(0\)\
\-\ resultant\\:\\ 0\\.01072560157215456\ \(0\)\
\-\ inability\\:\\ 0\\.010499990189589619\ \(0\)\
\-\ head\\:\\ 0\\.01037944886755416\ \(0\)\
\-\ t2\\:\\ 0\\.010357981879016497\ \(0\)\
\-\ account\\:\\ 0\\.010335191386300265\ \(0\)\
\-\ secondary\\:\\ 0\\.010231391719523801\ \(0\)\
\-\ occurring\\:\\ 0\\.01021941575188854\ \(0\)\
\-\ however\\:\\ 0\\.010190013086068825\ \(0\)\
\-\ densities\\:\\ 0\\.010145569550451346\ \(0\)\
\-\ ratio\\:\\ 0\\.010145569550451346\ \(0\)\
\-\ etiologies\\:\\ 0\\.010145569550451346\ \(0\)\
\-\ hiv\\:\\ 0\\.010145569550451346\ \(0\)\
\-\ greatest\\:\\ 0\\.010109580003735328\ \(0\)\
\-\ sickle\\:\\ 0\\.010109580003735328\ \(0\)\
\-\ to\\:\\ 0\\.010059420113218092\ \(0\)\
\-\ v\\:\\ 0\\.010039366250367039\ \(0\)\
\-\ epiphysis\\:\\ 0\\.010039366250367039\ \(0\)\
\-\ are\\:\\ 0\\.009977506402823142\ \(0\)\
\-\ vasculature\\:\\ 0\\.009938182342764156\ \(0\)\
\-\ emboli\\:\\ 0\\.009905489682955187\ \(0\)\
\-\ multifocal\\:\\ 0\\.009841564708330603\ \(0\)\
\-\ therapy\\:\\ 0\\.009784328891822755\ \(0\)\
\-\ damage\\:\\ 0\\.009779492894897514\ \(0\)\
\-\ accumulation\\:\\ 0\\.009749118944165275\ \(0\)\
\-\ facet\\:\\ 0\\.009719169817881035\ \(0\)\
\-\ \\:\\:\\ 0\\.009681154740819401\ \(0\)\
\-\ occasional\\:\\ 0\\.0096604996376067\ \(0\)\
\-\ fracture\\:\\ 0\\.009649140600739951\ \(0\)\
\-\ developing\\:\\ 0\\.009575402574117375\ \(0\)\
\-\ remaining\\:\\ 0\\.009520493729120935\ \(0\)\
\-\ nuclear\\:\\ 0\\.009440683461889176\ \(0\)\
\-\ mechanism\\:\\ 0\\.009414727657751393\ \(0\)\
\-\ factor\\:\\ 0\\.00933869620495287\ \(0\)\
\-\ types\\:\\ 0\\.00933869620495287\ \(0\)\
\-\ develop\\:\\ 0\\.009125570733117682\ \(0\)\
\-\ bone\\:\\ 0\\.009093938678628994\ \(0\)\
\-\ osteoarthritis\\:\\ 0\\.009080958127330013\ \(0\)\
\-\ undergoing\\:\\ 0\\.008973331072124682\ \(0\)\
\-\ disease\\:\\ 0\\.00897261803778825\ \(0\)\
\-\ replacement\\:\\ 0\\.008931750588490633\ \(0\)\
\-\ poorly\\:\\ 0\\.008931750588490633\ \(0\)\
\-\ bilateral\\:\\ 0\\.008881446378220317\ \(0\)\
\-\ lead\\:\\ 0\\.00877306114062399\ \(0\)\
\-\ fell\\:\\ 0\\.008754026991978924\ \(0\)\
\-\ leading\\:\\ 0\\.008754026991978924\ \(0\)\
\-\ disorders\\:\\ 0\\.008754026991978924\ \(0\)\
\-\ \\,\\:\\ 0\\.008695184117257624\ \(0\)\
\-\ \\;\\:\\ 0\\.008674180678597833\ \(0\)\
\-\ 90\\:\\ 0\\.008625324799110178\ \(0\)\
\-\ steroids\\:\\ 0\\.00860755434340419\ \(0\)\
\-\ dislocation\\:\\ 0\\.00860755434340419\ \(0\)\
\-\ involves\\:\\ 0\\.008503921493592949\ \(0\)\
\-\ idiopathic\\:\\ 0\\.008341622051688166\ \(0\)\
\-\ x\\-ray\\:\\ 0\\.008249836817358868\ \(0\)\
\-\ poor\\:\\ 0\\.008234914613255885\ \(0\)\
\-\ factors\\:\\ 0\\.008220095677828531\ \(0\)\
\-\ numerous\\:\\ 0\\.008205378591559233\ \(0\)\
\-\ sclerotic\\:\\ 0\\.008190761963999491\ \(0\)\
\-\ fall\\:\\ 0\\.008049834301109615\ \(0\)\
\-\ their\\:\\ 0\\.008009303230690946\ \(0\)\
\-\ development\\:\\ 0\\.007969525103125773\ \(0\)\
\-\ addition\\:\\ 0\\.007757091162904258\ \(0\)\
\-\ etiology\\:\\ 0\\.0077452278216288495\ \(0\)\
\-\ limited\\:\\ 0\\.007721696512045134\ \(0\)\
\-\ oral\\:\\ 0\\.007710027122821227\ \(0\)\
\-\ best\\:\\ 0\\.007698420982629922\ \(0\)\
\-\ taken\\:\\ 0\\.007630074937729912\ \(0\)\
\-\ absence\\:\\ 0\\.007607769239960627\ \(0\)\
\-\ arteries\\:\\ 0\\.0075747403955802595\ \(0\)\
\-\ levels\\:\\ 0\\.0075530008421241185\ \(0\)\
\-\ results\\:\\ 0\\.007386600447418944\ \(0\)\
\-\ range\\:\\ 0\\.007366680977049964\ \(0\)\
\-\ vessels\\:\\ 0\\.007366680977049964\ \(0\)\
\-\ motion\\:\\ 0\\.007356790300698156\ \(0\)\
\-\ uptake\\:\\ 0\\.007269771787353774\ \(0\)\
\-\ seen\\:\\ 0\\.0072318099146367896\ \(0\)\
\-\ pressure\\:\\ 0\\.007186151841161326\ \(0\)\
\-\ \\?\\:\\ 0\\.007141069594485025\ \(0\)\
\-\ subsequent\\:\\ 0\\.00712329913877904\ \(0\)\
\-\ process\\:\\ 0\\.007045108104571123\ \(0\)\
\-\ 50\\:\\ 0\\.006961451855768319\ \(0\)\
\-\ occur\\:\\ 0\\.006865196207240983\ \(0\)\
\-\ compression\\:\\ 0\\.006849566009207552\ \(0\)\
\-\ 8\\:\\ 0\\.006841793486615308\ \(0\)\
\-\ pain\\:\\ 0\\.0067041209905614645\ \(0\)\
\-\ reported\\:\\ 0\\.006670395825644137\ \(0\)\
\-\ weight\\:\\ 0\\.006558770417860526\ \(0\)\
\-\ labs\\:\\ 0\\.00636397003626368\ \(0\)\
\-\ cause\\:\\ 0\\.006191140527948536\ \(0\)\
\-\ although\\:\\ 0\\.006179720086887803\ \(0\)\
\-\ possible\\:\\ 0\\.006162702824162896\ \(0\)\
\-\ is\\:\\ 0\\.006020243879922116\ \(0\)\
\-\ surrounding\\:\\ 0\\.0060153431785112755\ \(0\)\
\-\ radiation\\:\\ 0\\.006004820662874382\ \(0\)\
\-\ the\\:\\ 0\\.005920740244266629\ \(0\)\
\-\ onset\\:\\ 0\\.005776062582280836\ \(0\)\
\-\ such\\:\\ 0\\.005720198693449363\ \(0\)\
\-\ 1\\.\\:\\ 0\\.005715608493142615\ \(0\)\
\-\ approximately\\:\\ 0\\.005661280142517308\ \(0\)\
\-\ severe\\:\\ 0\\.005630213704638125\ \(0\)\
\-\ age\\:\\ 0\\.0055694011253625405\ \(0\)\
\-\ fat\\:\\ 0\\.005565122747069879\ \(0\)\
\-\ renal\\:\\ 0\\.005497806315756037\ \(0\)\
\-\ treated\\:\\ 0\\.005477196651143168\ \(0\)\
\-\ decreased\\:\\ 0\\.005440591868789207\ \(0\)\
\-\ changes\\:\\ 0\\.005244214081873791\ \(0\)\
\-\ two\\:\\ 0\\.0052405379820471215\ \(0\)\
\-\ focal\\:\\ 0\\.005225896368604715\ \(0\)\
\-\ following\\:\\ 0\\.0051933142546063136\ \(0\)\
\-\ all\\:\\ 0\\.005175425030902122\ \(0\)\
\-\ region\\:\\ 0\\.00516831097909917\ \(0\)\
\-\ scan\\:\\ 0\\.005122636960241924\ \(0\)\
\-\ an\\:\\ 0\\.005060663230341456\ \(0\)\
\-\ blood\\:\\ 0\\.004994456258049892\ \(0\)\
\-\ one\\:\\ 0\\.004958739578823649\ \(0\)\
\-\ cell\\:\\ 0\\.004942699596534232\ \(0\)\
\-\ signal\\:\\ 0\\.004824570300369976\ \(0\)\
\-\ than\\:\\ 0\\.004794537162565897\ \(0\)\
\-\ common\\:\\ 0\\.004788580753653956\ \(0\)\
\-\ who\\:\\ 0\\.0047708102979479704\ \(0\)\
\-\ of\\:\\ 0\\.004739983330110878\ \(0\)\
\-\ for\\:\\ 0\\.004683778256805451\ \(0\)\
\-\ both\\:\\ 0\\.00467280511924223\ \(0\)\
\-\ \\(\\:\\ 0\\.004640439354885614\ \(0\)\
\-\ \\)\\:\\ 0\\.00458375391079211\ \(0\)\
\-\ more\\:\\ 0\\.004576394666621342\ \(0\)\
\-\ noted\\:\\ 0\\.004337090339298916\ \(0\)\
\-\ associated\\:\\ 0\\.004317906984813066\ \(0\)\
\-\ was\\:\\ 0\\.004232451915262042\ \(0\)\
\-\ other\\:\\ 0\\.0042176414319110254\ \(0\)\
\-\ mri\\:\\ 0\\.004204016819945653\ \(0\)\
\-\ can\\:\\ 0\\.004150369063102933\ \(0\)\
\-\ well\\:\\ 0\\.004139359642331158\ \(0\)\
\-\ this\\:\\ 0\\.0041162193289684505\ \(0\)\
\-\ but\\:\\ 0\\.003902576661742051\ \(0\)\
\-\ right\\:\\ 0\\.0038613777692094934\ \(0\)\
\-\ and\\:\\ 0\\.003854582563859067\ \(0\)\
\-\ surgical\\:\\ 0\\.003846299293900329\ \(0\)\
\-\ female\\:\\ 0\\.003761799296462171\ \(0\)\
\-\ treatment\\:\\ 0\\.0037036765730211717\ \(0\)\
\-\ patient\\:\\ 0\\.0036684879268367794\ \(0\)\
\-\ images\\:\\ 0\\.0035102010534247413\ \(0\)\
\-\ within\\:\\ 0\\.0034906454141029586\ \(0\)\
\-\ male\\:\\ 0\\.0033087913016862382\ \(0\)\
\-\ that\\:\\ 0\\.0031605583052651464\ \(0\)\
\-\ on\\:\\ 0\\.003100175641821962\ \(0\)\
\-\ by\\:\\ 0\\.003046832769260974\ \(0\)\
\-\ normal\\:\\ 0\\.002868549153317133\ \(0\)\
\-\ be\\:\\ 0\\.002821748872256808\ \(0\)\
\-\ there\\:\\ 0\\.002723159649817963\ \(0\)\
\-\ a\\:\\ 0\\.002547750332881807\ \(0\)\
\-\ with\\:\\ 0\\.002505442742824191\ \(0\)\
\-\ at\\:\\ 0\\.0024791502201962166\ \(0\)\
\-\ or\\:\\ 0\\.0021445883275454125\ \(0\)\
\-\ \\.\\:\\ 0\\.0017483711568286172\ \(0\)\
